TY -的T1的影响与残疾后遗症复发,与健康有关的生活质量,和疲劳与复发形式的人口使用数据从TEMSO多发性硬化症,一个关键三期Teriflunomide试验(P07.082) JF -神经学乔-神经病学SP - P07.082 LP - P07.082六世- 78 - 1补充AU -亚伦米勒AU -弗雷德·卢布林盟保罗·奥康纳AU -克里斯汀Taniou盟凯瑟琳Dive-Pouletty Y1 - 2012/04/26 UR - //www.ez-admanager.com/con首页tent/78/1_Supplement/P07.082.abstract N2 -目的:评估复发的影响与后遗症(investigator-defined)残疾,疲劳,和患者的健康相关生活质量(HR-QoL)复发的多发性硬化症(RMS)形式。背景不完全恢复复发导致某种程度的残疾。Teriflunomide是一种新型的口腔疾病修饰治疗治疗RMS的发展。2年期TEriflunomide多发性硬化症口服(TEMSO) (N = 1088)的研究表明,TEriflunomide复发年率减少了祝辞(术中;0.001 vs安慰剂)30%;teriflunomide 14毫克复发的年率后遗症减少了53%(术中;0.0001 vs安慰剂)。设计/方法:意向处理人口(N = 1086)进行了分析:患者无复发(组1 = 607);患者复发(s)但不后遗症(组2 = 277);和≥1复发患者后遗症(组3 = 202)。扩大残疾状态量表(eds)得分,疲劳影响量表(FIS)总分数和HR-QoL (EQ-5D /效用评分(衡量健康满意度))进行评估。意味着从基线(CfB)星期108进行了测试研究。结果:基线特征非常相似的跨组:37-39岁; 8.5–8.9 years since first symptom; 2.1–2.5 relapses within the past 2 years; FIS total score: 50–53; utility score: 0.71–0.72. After 2 years, a significantly greater deterioration in EDSS was observed in group 3 (CfB=0.73) compared with group 2 (CfB=0.14; p<0.0001) and group 1 (CfB=-0.04; p<0.0001). A significantly greater decline in FIS was also observed in group 3 (CfB=8.9) compared with group 2 (CfB=1.4; p<0.05) and group 1 (CfB=-3.0; p<0.0001). Considering utility, a trend toward a greater decline was observed in group 3 (CfB=-0.05) compared with group 2 (CfB=-0.02; p=ns) and group 1 (CfB=0.03; p<0.0001).Conclusions: Patients with relapse(s) with sequelae showed greater deterioration in disability (EDSS) and fatigue (FIS) and a trend toward greater decline in EQ-5D than other groups. Relapses with sequelae may have an important negative impact on patients' experience of MS.Supported by: sanofi-aventis.Disclosure: Dr. Miller has received personal compensation for activities with Acordia Therapeutics, Avanir, Biogen Idec, Chelsea Therapeutics, EMD Serono, GlaxoSmithKline, La-Ser, Merck Serono, Novartis, Nuron BiotechONO, Pfizer, Sanofi-Aventis, and Teva Neuroscience. Dr. Miller has received personal compensation in an editorial capacity for Continuum and Real Living with Multiple Sclerosis. Dr. Miller has received research support from Acorda, Biogen Idec, Genentech, Genzyme, Novartis, Roche, Sanofi-Aventis, and Teva Neuroscience. Dr. Lublin has received personal compensation for activities with Bayer HealthCare Pharmaceuticals, Biogen Idec, EMD Serono, Novartis, Pfizer, Teva Neuroscience, Genmab, Medicinova, Actelion, Allozyne, Sanofi, Acorda, Questcor, Avanir, Roche, Celgene, Abbott, MorphoSys, Johnson & Johnson, Revalesio, Coronado Bioscience, Genzyme, and MedImmune as a consultant.Dr. Lublin has received personal compensation in an editorial capacity for Elsevier: Multiple Sclerosis and Related Diseases. Dr. O'Connor has received personal compensation for activities with Abbott Labratories, Inc., Bayer Pharmaceuticals Corporation, Biogen Idec, BioMS, Cognosci, Daiichi Pharmaceuticals Corporation, Serono, Inc., Genentech, Inc., Genmab, Novartis, Roche Diagnostics Corporation, Sanofi-Aventis Pharmaceuticals, Inc., Teva Neuroscience, Warburg Pincus and Wyeth Pharmaceuticals as a consultant. Dr. O'Connor has received research support from Abbott Labratories, Bayer Pharmaceuticals Corporation, Biogen Idec, BioMS, Cognosci, Daiichi Pharmaceutical Corporation, Serono, Inc., Genentech, Inc., Genmab, Novartis, Roche Diagnostics Corporation, Sanofi-Aventis Pharmaceuticals, Teva Neuroscience, Warburg Pincus and Wyeth Pharmaceuticals. Dr. Taniou has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc. as an employee. Ms. Dive-Pouletty has received personal compensation for activities with Sanofi-Aventis.Thursday, April 26 2012, 14:00 pm-18:30 pm ER -